Email Us Here

FDA Report Cautioning Long-Term Use of Fosamax and Other Bisphosphonate Drugs Acknowledged by Rottenstein Law Group

The Rottenstein Law Group has learned of a new FDA report cautioning against the long-term use of Fosamax and other bisphosphonate drugs for the treatment of osteoporosis.